Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Mithra Pharmaceuticals S.A.
  6. News
  7. Summary
    MITRA   BE0974283153

MITHRA PHARMACEUTICALS S.A.

(MITRA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mithra Pharmaceuticals S A : Announces the Appointment of its Representative to Mayne Pharma's Board of Directors

10/05/2021 | 11:16am EST

Liege, Belgium - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, is pleased to announce that it has joined the Board of Mayne Pharma Group Limited, in accordance with the license and supply agreement to commercialize Nextstellis (E4/DRSP) oral contraceptive in the United States1 . As Mayne Pharma's largest shareholder (9.6% stake), Mithra has appointed Dr. Carolyn Myers as Director on the Board, as well as on the joint steering committee related to the commercialization and continued development of Nextstellis.

Dr. Myers, a U.S. resident, has been supporting Mithra's business development and marketing strategy for several years. She is an experienced pharmaceutical executive having held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). With over 30 years of experience in the pharmaceutical industry, she is currently CEO of FendX technologies, a medical technology company formed to develop and commercialize products using a unique pathogenrepelling technology. She is also Principal of BioEnsemble, providing consulting services to small and mid-size pharma, biotech and medical technology companies. Previously, she held the positions of Vice President of Global Alliance Management and International Business Development at Allergan, Vice President of Marketing at Forest Laboratories, President of Dey Laboratories and President of Mylan Technologies. She holds a Ph.D. from the University of British Columbia and a Master's in Business Administration from Rutgers University.

Commenting on her appointment, Dr. Myers said: 'I am pleased to be joining the Board at this important time in Mayne Pharma's development. As nominee of the Company's largest shareholder, our interests are aligned. I am committed to supporting the successful commercialization of Nextstellis oral contraceptive in the world's largest pharmaceutical market.'

Mayne Pharma's Chair Mr. Frank Condella said: 'We are delighted to welcome Carolyn to the Board of Mayne Pharma. Carolyn has a distinguished track record of success in creating, growing, and leading healthcare businesses. She has a deep experience in business development, sales and marketing, strategy, portfolio management and R&D and has led the launch of over 20 brand products.'

Contact:

Benoit Mathieu

IRO

T: +32 473 35 80 18

E: investorrelations@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen Estetrol in a wide range of applications in women health and beyond (Covid-19, neuroprotection...). Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liege, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements'. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes', 'estimates,' 'anticipates', 'expects', 'intends', 'may', 'will', 'plans', 'continue', 'ongoing', 'potential', 'predict', 'project', 'target', 'seek' or 'should', and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
MAYNE PHARMA GROUP LIMITED -1.69% 0.29 End-of-day quote.-15.94%
MITHRA PHARMACEUTICALS S.A. -2.13% 18.42 Real-time Quote.-6.50%
All news about MITHRA PHARMACEUTICALS S.A.
11/10Mithra organizes its Investor Day on November 29, 2021
PU
10/22MITHRA PHARMACEUTICALS S A : Announces Estelle Launch in Belgium
AQ
10/21MITHRA PHARMACEUTICALS S A : Announces Estelle® Launch in Belgium
PU
10/15MITHRA PHARMACEUTICALS S A : The Board of Directors confirms Leon Van Rompay as Mithra's C..
PU
10/07MITHRA PHARMACEUTICALS S A : Provides FDA Update on Myring
AQ
10/07MAYNE PHARMA : Provides fda update on generic nuvaringo
AQ
10/06MITHRA PHARMACEUTICALS S A : Provides FDA Update on Myring®
PU
10/05MITHRA PHARMACEUTICALS S A : Announces the Appointment of its Representative to Mayne Phar..
AQ
10/04MITHRA PHARMACEUTICALS S A : Announces the Appointment of its Representative to Mayne Phar..
PU
09/27MITHRA PHARMACEUTICALS S A : Announces Topline Results for COVID-19 Phase II Study
AQ
More news
Financials
Sales 2021 61,8 M 69,7 M 69,7 M
Net income 2021 -46,2 M -52,2 M -52,2 M
Net cash 2021 69,2 M 78,1 M 78,1 M
P/E ratio 2021 -20,7x
Yield 2021 -
Capitalization 811 M 918 M 915 M
EV / Sales 2021 12,0x
EV / Sales 2022 2,73x
Nbr of Employees 300
Free-Float 57,1%
Chart MITHRA PHARMACEUTICALS S.A.
Duration : Period :
Mithra Pharmaceuticals S.A. Technical Analysis Chart | MITRA | BE0974283153 | MarketScreener
Technical analysis trends MITHRA PHARMACEUTICALS S.A.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 18,42 €
Average target price 34,73 €
Spread / Average Target 88,6%
EPS Revisions
Managers and Directors
Leon van Rompay Chief Executive Officer
Christophe Maréchal Chief Financial Officer
Ajit S. Shetty Chairman
Graham K. Dixon CSO, Head-Research & Development
Koen Hoffman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MITHRA PHARMACEUTICALS S.A.-6.50%918
CSL LIMITED10.18%101 196
WUXI BIOLOGICS (CAYMAN) INC.0.58%56 285
SAMSUNG BIOLOGICS CO.,LTD.5.33%48 100
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-0.80%35 680